

In the Claims

Claims 1 to 13 (Cancelled)

14. (Currently Amended) A method for treating disseminated intravascular coagulation disorders in patients in need of such treatment, comprising administering an effective amount of an anhydridized serine protease which is capable of inhibiting the reaction of a serine protease with a substrate thereof by binding itself to said substrate of serine protease in competition with said serine protease ~~a serine protease inhibitor of claim 4.~~
15. (Currently Amended) The method of claim 14 wherein said ~~serine protease inhibitor~~ anhydridized serine protease is selected from the group consisting of anhydridized activated blood coagulation factor II, anhydridized blood coagulation factor VII, anhydridized activated blood coagulation factor IX, and anhydridized blood coagulation factor X ~~the serine protease inhibitor of claim 5.~~
16. (Currently Amended) The method of claim 14 wherein said ~~serine protease inhibitor~~ anhydridized serine protease is one wherein the site of anhyridization of said anhydridized serine protease is made solely of an active serine residue ~~the serine protease inhibitor of claim 6.~~
17. (Currently Amended) The method of claim 14 wherein said ~~serine protease inhibitor~~ anhydridized serine protease is obtained by a method which includes

(1) a step of inducing reaction of the active serine residue site of a serine protease with an inhibitor,

(2) a step of performing an alkali treatment, and

(3) a step of performing collection, wherein said method also executes said steps sequentially in the order mentioned, and at least step (3) is carried out in the presence of at least one of polyhydric alcohols or saccharides

~~the serine protease inhibitor of claim 7.~~

18. (Currently Amended) The method of claim 14 wherein said ~~serine protease inhibitor~~ anhydridized serine protease is obtained by a method which includes

(1) a step of inducing reaction of the active serine residue site of a serine protease with an inhibitor,

(2) a step of performing an alkali treatment which is carried out at a pH value in the range of 11.0-13.5, and

(3) a step of performing collection, wherein said method also executes said steps sequentially in the order mentioned, and at least step (3) is carried out in the presence of at least one of polyhydric alcohols or saccharides

~~the serine protease inhibitor of claim 8.~~

Application No. 10/018,875
Attorney Docket No. P 28,173 USA

July 30, 2004
Art Unit 1652

19. (Cancelled)
20. (New) A method for resisting a digestive enzyme in patient in need of such treatment, comprising administering an effective amount of an anhydridized serine protease which is capable of inhibiting the reaction of a serine protease with a substrate thereof by binding itself to said substrate of serine protease in competition with said serine protease.

Application No. 10/018,875
Attorney Docket No. P 28,173 USA

July 30, 2004
Art Unit 1652

In the Description

In an August 1, 2003 Action, the Examiner remarked that the descriptive portion of the specification and abstract were an inadequate translation of a foreign document and objected thereto because she considered it to contain poor grammar and sentence construction. While applicants did amend the specification and abstract, the Examiner, in her latest March 30, 2004 Action, maintained her objection thereto. Accordingly, applicants submit the attached substitute descriptive portion of the specification and abstract in accordance with 37 C.F.R. §1.125(a). No new matter has been added.